1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends

Biological Therapies for Cancer: Technologies and Global Markets

  • January 2015
  • 346 pages
  • ID: 196579

Summary

Table of Contents

REPORT HIGHLIGHTS

The global market for biologic cancer treatment totaled about $51.2 billion in 2014 and is expected to reach $66.4 billion in 2019, registering a compound annual growth rate (CAGR) of 5.4% for the period 2014-2019.
This report provides:
An overview of the global markets and technologies for biological therapies for cancer
Analyses of global market trends, with data from 2013 and 2014, and projections of compound annual growth rates (CAGRs) through 2019.
Detailed analyses of products in the market, market structure and competitive environments, cancer markets in newly emerging therapeutics, and analysis of biosimilars and their impact on the market.
Details concerning the strengths, weaknesses, opportunities, and threats facing various cancer biotherapeutics already on the market.
A look at major issues involved in the research and development (R&D) of more effective cancer therapeutics, and new cancer therapeutics in development and in clinical trials.
Comprehensive profiles of major players in the cancer biotherapeutics field.

SCOPE AND FORMAT

This report provides an update on BIO048B Biological Therapies for Cancer: Technologies and Global Markets. It reviews global markets for biologic therapeutics for cancer and forecasts trends for the use of biologics and cancer treatments through 2019. It discusses important biologics, market share by cancer type, products on the market, market share by company, statistical information for cancer types prevalent globally, with special emphasis on the U.S. market. It also includes current issues and trends affecting the industry, costs and factors influencing demand. The report covers biological products in development, biological products in clinical trials, and currently marketed and late-stage development biologic cancer products.
The market and sales data for various years gives strong support for the research and development (R&D) program and the move toward biologic treatment for cancer, as well as within biologic toward human monoclonal antibodies, vaccines and interferons.

The biologic drug classes discussed in this report with special focus on cancer treatment are:

Monoclonal antibodies.
Vaccines.
Erythropoietin.
Colony stimulating factors.
Interleukins and interferons.
The following approaches to cancer therapeutics are excluded in the report:
Chemotherapy.
Alkylating agents.
Antimetabolites.
Cytotoxic agents.
Plant derivatives and hormone therapy corticosteroids.
Hormone antagonists/antagonists aromatase inhibitors.
Radiation therapy.
Adjunctive therapy.
Biological therapies for treatment of other diseases will not be addressed in this report.

The report also covers biological products in development, biological products in clinical trials, and currently marketed and late-stage development biologic cancer products, including:
Treatment trends and sales patterns across major cancer indications for Japan, Europe E.U.5 nations (i.e., France, Germany, Italy, Spain, the U.K.), the U.S. and the rest of the world (ROW).
Market performance of major pharmaceutical companies.
Forecast sales of leading products across major indications to 2019.
Biosimilars and their impact on currently marketed cancer biotherapeutics.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Cancer Supportive Care Sector: Worldwide Forecast until 2021

  • $ 3500
  • Industry report
  • September 2017
  • by Infiniti Research Limited

About Cancer Supportive CareCancer supportive care drugs are used for the treatment of adverse effects caused due to the cancer treatment such as chemotherapy-induced anemia, CINV, bone metastasis, cance ...

Clinical Research in Endometrial Cancer in H2, 2017

  • $ 2500
  • Industry report
  • August 2017
  • by GlobalData

Endometrial Cancer Global Clinical Trials Review, H2, 2017SummaryGlobalData’s clinical trial report, “Endometrial Cancer Global Clinical Trials Review, H2, 2017" provides an overview of Endometrial ...

Clinical Research in Extrahepatic Bile Duct Cancer in H2, 2017

  • $ 2500
  • Industry report
  • August 2017
  • by GlobalData

Extrahepatic Bile Duct Cancer Global Clinical Trials Review, H2, 2017SummaryGlobalData’s clinical trial report, “Extrahepatic Bile Duct Cancer Global Clinical Trials Review, H2, 2017" provides an overview ...


ref:plp2015

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.